NCT06966024View on ClinicalTrials.gov

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 27, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2029

Conditions
Renal Cell CarcinomaUrothelial CarcinomaCastration-resistant Prostate Cancer
Interventions
DRUG

DCC-2812

Administered orally

Trial Locations (2)

78229

RECRUITING

NEXT Oncology, San Antonio

78758

RECRUITING

NEXT Austin, Austin

Sponsors
All Listed Sponsors
lead

Deciphera Pharmaceuticals, LLC

INDUSTRY

NCT06966024 - Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | Biotech Hunter | Biotech Hunter